Tab udiliv mg and freq
Reading File
Udiliv (Ursodeoxycholic acid / UDCA) is typically available as 150 mg and 300 mg tablets, dosed at 10-15 mg/kg/day in 2-3 divided doses.
Searching sources...
Finding Sources
Searching the Web
Udiliv ursodeoxycholic acid tablet mg dosage frequency indications
Tab Udiliv (Ursodeoxycholic Acid / UDCA)
Manufacturer: Abbott India Ltd
Available Strengths
| Strength | Common Use |
|---|---|
| 150 mg | Paediatric dosing, titration |
| 300 mg | Standard adult dosing |
Dosage by Indication
| Indication | Dose | Frequency |
|---|---|---|
| Primary Biliary Cholangitis (PBC) | 13-15 mg/kg/day | Divided in 2-4 doses with food |
| Gallstone dissolution | 10-15 mg/kg/day | OD at bedtime or BD |
| NAFLD / fatty liver | 10-15 mg/kg/day | BD or TDS |
| Intrahepatic cholestasis of pregnancy (ICP) | 10-15 mg/kg/day | BD-TDS |
| Primary Sclerosing Cholangitis (PSC) | 15-20 mg/kg/day | BD-TDS |
Typical adult prescription: Udiliv 300 mg - 1 tab BD or TDS after meals (for a ~60 kg patient, 300 mg TDS = 15 mg/kg/day)
Key Points
- Take after meals with water or milk
- Swallow whole - bitter taste if chewed
- Long-term therapy (months to years) required; do not stop early
- Monitor LFTs at 1, 3 months then 6-monthly
- Contraindicated in complete biliary obstruction, acute cholecystitis, biliary fistula
- Common side effects: diarrhoea, abdominal pain, sticky stools, rash
Dosing per FDA URSO prescribing information and NCBI StatPearls. The optimal dose for PBC is ~900 mg/day (13.5 mg/kg/day) per clinical trials.
Algarna sargova rheumt criteria
The user seems to be asking about Alarcon-Segovia rheumatoid criteria - likely the classification criteria for Mixed Connective Tissue Disease (MCTD) or possibly Undifferentiated Connective Tissue Disease (UCTD). Let me search for this.
Searching sources...
Finding Sources
Searching the Web
Alarcon-Segovia criteria MCTD mixed connective tissue disease rheumatology classification
Now let me get the full table from the Firestein & Kelley textbook:
Reading File
Reading File
Alarcon-Segovia Criteria for MCTD (Mixed Connective Tissue Disease)
Mandatory Serological Criterion
Anti-U1 RNP antibody titer ≥ 1:1600 (must be present)
Clinical Criteria (≥ 3 of the following 5 must be present)
| # | Clinical Feature |
|---|---|
| 1 | Swollen hands |
| 2 | Synovitis |
| 3 | Myositis |
| 4 | Raynaud's phenomenon |
| 5 | Sclerodactyly |
Important caveat: If hand swelling + Raynaud's + sclerodactyly are all present together, then synovitis and/or myositis must also be present to meet criteria (to avoid over-inclusion of pure SSc patients).
Performance
| Parameter | Value |
|---|---|
| Sensitivity | ~62.5% (rises to ~81% if myalgia substituted for myositis) |
| Specificity | 86.2% |
Alarcon-Segovia and Kahn criteria have the best specificity among the four MCTD classification sets (Sharp, Alarcon-Segovia, Kahn, Kasukawa). Kasukawa criteria are more sensitive but less specific.
Comparison of All Major MCTD Criteria (Summary)
| Criteria | Serology Required | Key Clinical Requirement |
|---|---|---|
| Alarcon-Segovia | Anti-RNP ≥ 1:1600 | ≥ 3 of 5 clinical features |
| Kahn | Anti-RNP + speckled ANA > 1:1200 | Raynaud's + ≥ 2 remaining features |
| Kasukawa | Anti-RNP positive | ≥1 common finding + ≥1 from 2 of 3 overlaps (SLE/SSc/PM) |
| Sharp | Anti-RNP (high titer) | Composite major/minor criteria scoring |
The "MCTD Overlap" Features to Remember
MCTD is an overlap of SLE + Systemic Sclerosis (SSc) + Polymyositis, hence the clinical features span all three.
Source: Firestein & Kelley's Textbook of Rheumatology, Table 87.3
This is a shared conversation. Sign in to Orris to start your own chat.